Biomedical subjects

A Condi-Paphiti

Publications and source records attributed to A Condi-Paphiti.

3 recordsLinked to original sources

PubMed1996

Ovarian surface serous papillary carcinomas: a clinicopathologic study.

Between 1982 and 1992, 129 patients with malignant epithelial ovarian tumors were reviewed with identification of 10 patients having surface papillary serous carcinoma of the ovary and one having peritoneal papillary carcinoma. The gross operative specimens, histopathologic condition, and treatment records were reviewed. All patients had disease involving the omentum, and the abdominal and pelvic peritoneum, and they all corresponded to stage III, according to FIGO. The median age at presentation was 58-years (age range, 43 to 73 years). All patients had a total abdominal hysterectomy and bilateral salpingo-oophorectomy, and all received chemotherapy. The median survival time for all patients was 15 months. Three patients are alive 3 to 4 years after the initial diagnosis. In conclusion, surface serous ovarian cancers and peritoneal papillary serous cancers have common histologic appearance and the same responsiveness to surgical therapy and to chemotherapy and should be treated similarly.

Adult↗

PubMedDate not supplied

Human papillomavirus identification and typing of both sexual partners.

OBJECTIVE: To investigate the efficacy of diagnostic methods for human papillomavirus (HPV) infection. STUDY DESIGN: The diagnostic methods were morphologic and immunohistochemical techniques and in situ hybridization. The first ones consisted of (1) a cytologic smear on the females, (2) cytologic examination of a urethral brushing on the males, (3) colposcopy on the females, and (4) histologic examination of the uterine cervix. RESULTS: A synchronous HPV infection was found in 50% of the sexual partners. HPV was detected also in 30% of cervical biopsies by immunohistochemistry. In situ hybridization was performed on both the cervical biopsies and urethral samples from the males. By this method the same subtype of the virus was observed in both sexes. The types of HPV were identified in 45% of 20 females and 80% of 20 males. Analytically, in men, 7 cases of HPV 6/11 types, 3 cases of 16/18, 5 cases of 31/33/35 and 1 case each of 16/18 and 31/33/35 were observed. In women, in 4 cases subtypes 6/11, in 2 cases types 16/18 and in 3 cases types 31/33/35 were identified. CONCLUSION: Male partners of women with HPV infection should be investigated in order to produce greater insight into HPV prevalence and the mechanisms of viral transmission.

Adult↗

PubMedDate not supplied

Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.

The efficacy and toxicity of treatment with 1400 +/- 100 MBq of Re-186-HEDP were evaluated in women with osseous metastatic breast cancer. The follow-up period was fourteen weeks. The efficacy of treatment was assessed by a) a pain and performance questionnaire that patients were asked to complete daily and b) a CT scan comparison of a randomly preselected osseous lesion before and 30 weeks after Re-186-HEDP i.v. application. The response to treatment was also evaluated by using the Kamofsky Index. Two out of fourteen women (14%) experienced loss of pain, 6 experienced obvious and 2 some improvement. No change was observed in 4 patients. Five patients manifested a flare response to treatment, with increase in pain within the first, 4 to 5 days after Re-186-HEDP administration. Five patients showed a decrease in platelet levels and absolute number of polymorphonuclear blood transfusion; no neurologic side effects were observed. Re-186-HEDP appears to be a useful new radiopharmaceutical for pain palliation induced by osseous metastases due to breast cancer. Compared to Sr-89 chloride efficacy, it provides longer-lasting analgesia, and when needed it can be reinjected with less risk due to its improved physico- and radiochemical properties.

Adult↗